Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 110

Similar articles for PubMed (Select 23479185)

1.

Cyclic variations of bone resorption mediators and markers in the different phases of the menstrual cycle.

Mozzanega B, Gizzo S, Bernardi D, Salmaso L, Patrelli TS, Mioni R, Finos L, Nardelli GB.

J Bone Miner Metab. 2013 Jul;31(4):461-7. doi: 10.1007/s00774-013-0430-4. Epub 2013 Mar 12.

PMID:
23479185
2.

Physiologic fluctuations of serum estradiol levels influence biochemical markers of bone resorption in young women.

Zittermann A, Schwarz I, Scheld K, Sudhop T, Berthold HK, von Bergmann K, van der Ven H, Stehle P.

J Clin Endocrinol Metab. 2000 Jan;85(1):95-101.

PMID:
10634371
3.

Changes in the serum sex steroids, IL-7 and RANKL-OPG system after bone marrow transplantation: influences on bone and mineral metabolism.

Baek KH, Oh KW, Lee WY, Tae HJ, Rhee EJ, Han JH, Cha BY, Kim YJ, Lee KW, Son HY, Kang SK, Kim CC, Kang MI.

Bone. 2006 Dec;39(6):1352-60. Epub 2006 Aug 14.

PMID:
16905375
4.

Variations in circulating osteoprotegerin and soluble RANKL during diurnal and menstrual cycles in young women.

Shimizu M, Onoe Y, Mikumo M, Miyabara Y, Kuroda T, Yoshikata R, Ishitani K, Okano H, Ohta H.

Horm Res. 2009;71(5):285-9. doi: 10.1159/000208802. Epub 2009 Apr 1.

PMID:
19339793
5.

Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates.

Alvarez L, Peris P, Guañabens N, Vidal S, Ros I, Pons F, Filella X, Monegal A, Muñoz-Gomez J, Ballesta AM.

Arthritis Rheum. 2003 Mar;48(3):824-8.

6.

Effects of the natural and artificial menstrual cycle on the production of osteoprotegerin and the bone resorptive cytokines IL-1beta and IL-6.

Abrahamsen B, Stilgren LS, Rettmer E, Bonnevie-Nielsen V, Beck-Nielsen H.

Calcif Tissue Int. 2003 Jan;72(1):18-23. Epub 2002 Oct 21.

PMID:
12384814
7.

Osteoprotegerin and RANKL in the pathogenesis of osteoporosis in patients with thalassaemia major.

Pietrapertosa AC, Minenna G, Colella SM, Santeramo TM, Renni R, D'Amore M.

Panminerva Med. 2009 Mar;51(1):17-23.

9.

Variations along the 24-hour cycle of circulating osteoprotegerin and soluble RANKL: a rhythmometric analysis.

Dovio A, Generali D, Tampellini M, Berruti A, Tedoldi S, Torta M, Bonardi S, Tucci M, Allevi G, Aguggini S, Bottini A, Dogliotti L, Angeli A.

Osteoporos Int. 2008 Jan;19(1):113-7. Epub 2007 Aug 17.

PMID:
17703272
10.

Serum soluble interleukin-6 receptor and biochemical markers of bone metabolism show significant variations during the menstrual cycle.

Gorai I, Taguchi Y, Chaki O, Kikuchi R, Nakayama M, Yang BC, Yokota S, Minaguchi H.

J Clin Endocrinol Metab. 1998 Feb;83(2):326-32.

PMID:
9467535
11.

Implications of measuring soluble receptor activators of nuclear factor-kappaB ligand and osteoprotegerin in bone metabolism of elderly women.

Chiba Y, Onouchi T, Ikeda T, Adachi J, Tamura Y, Horiuchi T.

Gerontology. 2009;55(3):275-80. doi: 10.1159/000196280. Epub 2009 Jan 22.

PMID:
19158438
12.

Changes in bone resorption during the menstrual cycle.

Chiu KM, Ju J, Mayes D, Bacchetti P, Weitz S, Arnaud CD.

J Bone Miner Res. 1999 Apr;14(4):609-15.

PMID:
10234583
13.

RANKL/RANK/OPG system and bone status in females with anorexia nervosa.

Ostrowska Z, Ziora K, Oświęcimska J, Swiętochowska E, Szapska B, Wołkowska-Pokrywa K, Dyduch A.

Bone. 2012 Jan;50(1):156-60. doi: 10.1016/j.bone.2011.09.054. Epub 2011 Oct 6.

PMID:
22001124
14.

Multiparameter analysis of serum levels of C-telopeptide crosslaps, bone-specific alkaline phosphatase, cathepsin K, osteoprotegerin and receptor activator of nuclear factor κB ligand in the diagnosis of osteoporosis.

Piatek S, Adolf D, Wex T, Halangk W, Klose S, Westphal S, Amthauer H, Winckler S.

Maturitas. 2013 Apr;74(4):363-8. doi: 10.1016/j.maturitas.2013.01.005. Epub 2013 Feb 4.

PMID:
23391500
15.

Maintained malnutrition produces a progressive decrease in (OPG)/RANKL ratio and leptin levels in patients with anorexia nervosa.

Muñoz-Calvo MT, Barrios V, García de Alvaro MT, Lefort M, Méndez-Dávila C, Argente J, de la Piedra C.

Scand J Clin Lab Invest. 2007;67(4):387-93.

PMID:
17558893
16.

Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women.

Rogers A, Saleh G, Hannon RA, Greenfield D, Eastell R.

J Clin Endocrinol Metab. 2002 Oct;87(10):4470-5.

PMID:
12364420
17.

Changes in RANKL/OPG/RANK gene expression in peripheral mononuclear cells following treatment with estrogen or raloxifene.

Bashir A, Mak YT, Sankaralingam S, Cheung J, McGowan NW, Grigoriadis AE, Fogelman I, Hampson G.

Steroids. 2005 Dec 1;70(13):847-55. Epub 2005 Jul 7.

PMID:
16005483
18.

Possible variation in bone resorption during the normal menstrual cycle.

Schlemmer A, Hassager C, Risteli J, Risteli L, Jensen SB, Christiansen C.

Acta Endocrinol (Copenh). 1993 Nov;129(5):388-92.

PMID:
8279219
19.

 Dehydroepiandrosterone sulfate, osteoprotegerin and its soluble ligand sRANKL and bone metabolism in girls with anorexia nervosa.

Ostrowska Z, Ziora K, Oświęcimska J, Swiętochowska E, Wołkowska-Pokrywa K.

Postepy Hig Med Dosw (Online). 2012 Sep 12;66:655-62.

20.

Serum OPG and RANKL levels before and after intravenous bisphosphonate treatment in Paget's disease of bone.

Martini G, Gennari L, Merlotti D, Salvadori S, Franci MB, Campagna S, Avanzati A, De Paola V, Valleggi F, Nuti R.

Bone. 2007 Feb;40(2):457-63. Epub 2006 Sep 18.

PMID:
16979395
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk